Exenatide, a glucagon-like peptide-1(GLP-1), is a second-line treatment for type 2 diabetes mellitus (DM) and has demonstrated clinical benefits for patients with PD in randomised controlled trials (RCT) in 2013 [10,11]. The gene discussed is GCG; the disease is Parkinson disease.